Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review

Shepherd J, Waugh N, Hewitson P
Record ID 32001000002
Authors' objectives:

To review the clinical effectiveness and cost-effectiveness of combination therapy with interferon alfa and ribavirin in patients with chronic hepatitis C.

Authors' recomendations: There is benefit associated with combination therapy and treatment can be cost-effective. It is appropriate to offer 6 months of combination therapy as first-line treatment to patients not previously treated with interferon and also to patients who have relapsed following a previous course of interferon. At 6 months, continuation of treatment should depend on factors that may predict a good sustained response.
Authors' methods: Systematic review
Project Status: Completed
URL for project:
Year Published: 2000
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Costs and Cost Analysis
  • Drug Therapy, Combination
  • Hepatitis C, Chronic
  • Interferon-alpha
  • Ribavirin
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
Contact Email:
Copyright: 2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.